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Abstract
Purpose: Prostate cancer is multifocal. However, there often exists a single dominant focus in the gland responsible for driving the
biology of the disease. Dose escalation to the dominant lesion is a proposed strategy to increase tumor control. We applied radiobi-
ological modeling to evaluate the dosimetric feasibility and benefit of dominant intraprostatic lesion simultaneous in-field boosts (DIL-
SIB) to the gross tumor volume (GTV), defined using a novel molecular positron emission tomography (PET) probe (18F-DCFPyL)
directed against prostate specific membrane antigen (PSMA).
Methods and Materials: Patients with clinically localized, biopsy-proven prostate cancer underwent preoperative [18F]-DCFPyL
PET/computed tomography (CT). DIL-SIB plans were generated by importing the PET/CT into the RayStation treatment
planning system. GTV-PET for the DIL-SIB was defined by the highest %SUVmax (percentage of maximum standardized uptake
value) that generated a biologically plausible volume. Volumetric arcebased plans incorporating prostate plus DIL-SIB treatment
were generated. Tumor control probability (TCP) and normal tissue complication probability (NTCP) with fractionation schemes
and boost doses specified in the FLAME (Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer;
NCT01168479), PROFIT (Prostate Fractionated Irradiation Trial; NCT00304759), PACE (Prostate Advances in Comparative
Evidence; NCT01584258), and hypoFLAME (Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0;
NCT02853110) protocols were compared.
Results: Comparative DIL-SIB plans for 6 men were generated from preoperative [18F]-DCFPyL PET/CT. Median boost GTV
volume was 1.015 cm3 (0.42-1.83 cm3). Median minimum (D99%) DIL-SIB dose for F35BS, F20BS, F5BS, and F5BSH were 97.3
Gy, 80.8 Gy, 46.5 Gy, and 51.5Gy. TCP within the GTV ranged from 84% to 88% for the standard plan and 95% to 96% for
the DIL-SIB plans. Within the rest of the prostate, TCP ranged from 89% to 91% for the standard plans and 90% to 92% for the
DIL-SIB plans. NTCP for the rectum NTCP was similar for the DIL-SIB plans (0.3%-2.7%) compared with standard plans
(0.7%-2.6%). Overall, DIL-SIB plans yielded higher uncomplicated TCP (NTCP, 90%-94%) versus standard plans (NTCP, 83%-
85%).
Conclusions: PSMA PET provides a novel approach to define GTV for SIB-DIL dose escalation. Work is ongoing to validate PSMA
PET-delineated GTV through correlation to coregistered postprostatectomy digitized histopathology.
 2019 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Prostate cancer (PCa) is a multifocal disease. Histo-
logic studies have reported that large prostate tumors are
frequently accompanied by small, well-differentiated
secondary tumors.1 Accordingly, external beam radia-
tion therapy (EBRT) for PCa has typically delivered a
uniform dose to the entire gland. Dose escalation is
correlated with a reduced risk of biochemical failure (BF)
in the range of 1.8% per gray increase.2 Whole-prostate
dose escalation is possible to doses 86 Gy, above
which bladder and rectal toxicity becomes intolerable.3
Unfortunately, locally recurrent disease is possible at
this dose, suggesting that further escalation is required to
obtain local tumor control.4,5
Whole-mount pathology and genomic studies support
the concept of a dominant intraprostatic lesion (DIL),
wherein the largest or most aggressive intraprostatic
lesion is responsible for driving the biology of the disease
and thus prognosis.6,7 Up to one-third of patients treated
with radical-intent EBRT for PCa will develop local
recurrence, with the DIL being the most common site of
recurrence.8,9 In the metastatic setting, Haffner et al10
tracked the clonal origin in a patient who died of metas-
tases from PCa and proved that all metastases arose from
a single prostatic lesion. Targeting the DIL with a boost
dose is considered an effective strategy for dose escalation
(and thus improved disease control) while respecting
organ-at-risk (OAR) constraints. Indeed, it has been re-
ported that dose distribution to the DIL is an independent
risk factor for BF after primary EBRT in patients with
PCa.11
In a recent meta-analysis, von Eyben et al9
concluded that a boost to the DIL was effective and
safe. Because the DIL constitutes a small portion of the
prostate, ultrahigh boost doses to 90 Gy were feasible
and appeared to be associated with improved outcomes.
One study, included in their meta-analysis, reported a
10-year disease-free survival rate of 98% with boost to
the DIL.
A systematic review of the literature by Bauman
et al12 demonstrated a large cohort of patients who have
been treated for PCa with the addition of boosts to
imaging-defined DILs. They note that there is a lack of
standardized, reproducible, and accurate intraprostatic
gross tumor volume (GTV) delineation guidelines.
Various technologies for image guided definition of a
DIL have been trialed, including contrast-enhanced
magnetic resonance imaging (MRI), magnetic reso-
nance spectroscopy, single-photon emission computer-
ized tomography (SPECT), and positron emission
tomography (PET)/computed tomography (CT). PET/CT
using radiotracers directed against prostate-specific
membrane antigen (PSMA; a type II transmembrane
protein encoded by the FOLH1 gene exhibiting 100- to
1000-fold overexpression in PCa13) has been shown to
outperform multiparametric MRI when correlated with
histology after prostatectomy.14-16
The aim of our study was to investigate the dosimetric
feasibility and predicted biological efficacy of simulta-
neous in-field boost (SIB) to the DIL using PSMA
PETdelineated GTVs in patients with primary PCa
where the DIL is defined pathologically after radical
prostatectomy. Plan comparisons were made using con-
ventional (1.8-2.0 Gy/d) fractionation, moderate hypo-
fractionation (2.5-3.0 Gy/d), and extreme
hypofractionation (7-8 Gy/d).
Methods and Materials
Patient selection and PET/CT imaging
As part of a prospective clinical trial, IGPC-2
(Multi-modality Prostate Cancer Image Guided In-
terventions), patients with clinically localized, biopsy-
proven PCa underwent preoperative [18F]-DCFPyL
PET/CT. Inclusion criteria were biopsy-proven prostate
adenocarcinoma and planned prostatectomy; exclusion
criteria included prior treatment with hormones or ra-
diation. All men were imaged at least 6 weeks after
biopsy and within the 6 weeks before surgery. The
multimodal imaging panel included dynamic contrast-
enhanced CT (standard 3 mm CT slice thickness; Dis-
covery VCT, GE Healthcare, Milwaukee, WI) to mea-
sure intraprostatic blood flow and develop quantitative
maps of [18F]-DCFPyL uptake, PET/CT (GE Health-
care), and PET/MRI (Siemens BIOGRAPH mMR,
Erlangen, Germany).
Structure delineation
To facilitate treatment planning, all CT and PET/CT
images were transferred to RayStation V6.1 (RaySearch
Inc.). The contouring of the prostate, bladder, rectum, and
femoral heads was performed by a radiation oncologist
based on the recommendations of the Radiation Therapy
Oncology Group.17 The clinical target volume (CTV)
included the prostate and proximal seminal vesicles. The
planning target volume (PTV) was created by adding a
uniform 5 mm margin to the CTV.18 The GTV based on
the PSMA PET for the DIL-SIB was defined by the
highest %SUVmax that generated a biologically plausible
volume (GTV composed of contiguous voxels without
gaps). The related PTV (PTVDIL) was created by adding a
uniform 5 mm margin to the GTV.
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Simulated treatment planning
Standard plans aiming to treat the entire CTV are
labeled ST, and plans including a boost to the DIL volume
are termed BS. Three fractionationsd77 Gy in 35 frac-
tions, 60 Gy in 20 fractions, and 35 Gy in 5 fractions
dwere considered for the standard plans (Table 1) and
are labeled F35ST, F20ST, and F5ST, respectively. The
prescriptions represent conventional, moderate, and
extreme hypofractionations. Treatment plans were pro-
duced for each standard fractionation using dose objec-
tives and constraints from the FLAME,19 PROFIT,20 and
PACE21 trials, respectively. The boost plan F35BS was
based on the FLAME trial. The prescriptions for boost
plans F20BS and F5BS were set to ensure a biological
effective dose equivalent to the F35BS protocol (assuming
an a/b ratio of 3 and no repopulation). An additional
5-fraction boost prescription of 50 Gy, F5BSH, was
incorporated to investigate the more contemporary Hypo-
FLAME trial (NCT02853110). The target coverage and
OAR constraints are given in Table E2 (available online
at https://doi.org/10.1016/j.adro.2019.09.004). All plans
were generated with the RayStation treatment planning
system, produced using volumetic modulated arc therapy.
The RayStation biology module was used to calculate
tumor control probability (TCP) and normal tissue
complication probability (NTCP) values. For detailed
information regarding these calculations please refer to
the radiobiology modeling and evaluation section of the
Supplementary Materials (available online at https://doi.
org/10.1016/j.adro.2019.09.004).
Statistical analysis
Median values and ranges were calculated for the
resulting dose-volume histogram (DVH) parameters, TCP
and NTCP. The parameters for the standard and boost
plans were compared using Wilcoxon signed-rank test
using Origin (OriginLab). The 2 distributions were
considered significantly different if the P values were less
than .05.
Results
Six patients underwent preoperative PSMA PET/CT
imaging (patients 1-6). Using National Comprehensive
Cancer Network criteria, 2 patients were high risk and 4
were intermediate risk. Standard whole-prostate and
OAR contours were created. DIL (GTV-PET) volumes
were delineated for boost using an average %SUVmax
of 30% (23%-40%). Median boost volumes were 1.015
cm3 (0.42-1.83 cm3). One patient (patient 5) had 2
separate GTV-PET volumes. The volumes, positions,
and distances from the rectum are given in Table E4
(available online at https://doi.org/10.1016/j.adro.201
9.09.004).
Comparative plans were generated for 6 patients
using the prior specified fractionation schedules. The
planning objectives and OAR dose constraints were met
by all standard plans and by the boost plans for patients
2, 4, 5, and 6. Patients 1 and 3 had DIL volumes in close
proximity to the rectum (0.2 mm and 3 mm, respec-
tively), and rectal dose constraints for boost plans could
not be achieved. In these cases, the dose constraints
were met when prescribing the dose to a modified
PTVDIL (modPTVDIL), defined as the PTVDIL 5 mm
away from the rectum. Despite the reduced PTVDIL
margins, GTV coverage (99% of the GTV covered by
the boost prescription dose) was maintained for all
cases and all boost protocols except the most hypo-
fractionated schedule (F5BSH). Increasing the boost
dose from 45.5 Gy (F5BS) to 50 Gy (F5BSH) was
achievable without exceeding the rectal dose con-
straints, except for patients 1 and 3. An example of dose
distribution and the related DVH for patient 4 is shown
in Figure 1. For all patients and dose fractionations, the
dose distributions around the rectum and bladder and
the corresponding DVHs display similar doses for both
standard and boost plans. The isodose lines higher than
50% of the prescribed dose were prioritized to be
similar between standard and boost protocols as the
risks of rectal toxicity are thought to have a dose-
response relationship in the intermediate- and high-
dose volumes.
The median dose to 99% of the GTV (D99%) in the
standard plans was 77 Gy, 61 Gy, and 36 Gy for F35ST,
F20ST, and F5ST, respectively. The D99% to GTV for the
corresponding boost plans was 97 Gy, 81 Gy, and 47
Table 1 Standard dose prescriptions to the PTV and total
dose prescription to the PTVDIL including the simultaneous
integrated boost




F35ST 77 Gy / 35 d 133.5 d
F35BS 77 Gy / 35 95 Gy / 35 133.5 181
F20ST 60 Gy / 20 d 120 d
F20BS 60 Gy / 20 79 Gy / 20 120 183
F5ST 35 Gy / 5 d 116.7
F5BS 35 Gy / 5 45.5 Gy / 5 116.7 183.5
F5BSH 35 Gy / 5 50 Gy / 5 116.7 216.7
Abbreviations: BED Z biologically equivalent dose; BS Z boost
plan; DIL Z dominant intraprostatic lesion; PTV Z planning target
volume; ST Z standard plan.
The related EQD2 and BED are calculated assuming an a/b equal to
3 and no repopulation.
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Gy. The median D99% for the 4 patients with F5BSH
boost was 51 Gy. The boosts increased the mean dose to
the GTV by 31%, 36%, 31%, and 48% for the F35BS,
F20BS, F5BS, and F5BSH protocols, respectively. The
corresponding increase of the mean dose to the prostate
excluding GTV (PROS-GTV) was 12%, 11%, 11%, and
14%. The differences in doses were statistically sig-
nificant for both volumes (P < .05). The mean doses to
the GTV and D1cc to the rectum and bladder are shown
in Table E5 (available online at https://doi.org/10.1016/
j.adro.2019.09.004). The differences between standard
and boost fractionations in rectum D1cc were 3%, 5%,
6%, and 6%, and the differences in bladder D1cc were
1%, 2%, 3%, and 3%. The physical DVH parameters
for rectum and bladder were also compared for V50Gy
and V70Gy; no differences were statistically significant
(P > .05).
DVHs in equivalent 2 Gy per fraction doses (EQD2)
were generated to compare the biological effectiveness
of the different fractionation schemes. DVHs for GTV,
PROS-GTV, rectum, and bladder are shown in Figure 2.
As prescriptions were adapted to be radiobiologically
similar, boost dose DVHs are similar between protocols.
The tails observed in the PROS-GTV DVH represent the
dose fall-off outside the boost region. Figures E4, E5,
and E6 (available online at https://doi.org/10.1016/j.
adro.2019.09.004) show the comparison of the EQD2
DVHs for the GTV, rectum, and bladder for each
patient.
Figure 2 illustrates the significant increase in the GTV
dose in the boost plans. EQD2 mean doses to the GTV
and PROS-GTV and D1cc, V50Gy, and V70Gy to both






























































Figure 1 Dose distributions (sagittal projections) and corresponding DVHs for different fractionations for patient 4. The first and
second rows represent standard and DIL boost plans, respectively. The third row contains comparative DVHs for the CTV, GTV,
rectum, and bladder. The DVH for the 5 fractions regimen (F5BS) includes the higher dose Hypo-FLAME (F5BSH) plan results as well
(dotted lines). Abbreviations: CTV Z clinical target volume; DIL Z dominant intraprostatic lesion; DVH Z dose-volume histogram;
GTV Z gross tumor volume; Hypo-FLAME Z Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0.
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The boosts increased the EQD2 to the GTV to approxi-
mately 120 Gy. The mean GTV dose for F5BSH was
approximately 143 Gy. The corresponding rectal and
bladder DVHs were similar for both the standard and the
boost plans.
Figure 3 displays TCP values for the GTV and
PROS-GTV compared with NTCP for both rectum and
bladder. The effectiveness of the treatment protocols is
assessed using the complication factor Pþ, which rep-
resents the probability of tumor control without rectal
complications. For the standard plans, the mean TCPs
for the GTV were 87%, 84%, and 84% for F35ST,
F20ST, and F5ST. The boost increased the TCPs to
approximately 94% for all 3 protocols. The corre-
sponding mean TCP for F5BSH was approximately 96%.
The TCP for PROS-GTV was approximately 90% for
the standard plans and 91% for the boost plans. The
TCPs for PROS-GTV are higher than for the GTV
because of the lower clonogenic cell density. The dif-
ferences in NTCP between standard and boost plans
were not significant. The mean probability of uncom-
plicated tumor control (Pþ) for the standard plans was
85%, 82%, and 83% for F35ST, F20ST, and F5ST,
respectively. The corresponding values for the boost
plans (F35BS, F20BS, and F5SS) were 92%, 92%, and
94%. The mean Pþ for F5BSH was 96%.
Discussion
In this study we applied radiobiological modeling to
evaluate the dosimetric feasibility and biological effective-
ness of DIL-SIB to GTVs defined using a novel molecular
PET probe directed against PSMA. TCP and NTCP were
calculated for 6 patients with prescriptions ranging from
conventionally to extremely hypofractionated.
Optimal identification of the DIL is an area of ongoing
discordance. In 2013, a systematic review by Bauman
et al12 identified 13 studies describing 11 unique patient
series with a total of 833 patients receiving an imaging
defined boost to the DIL. They noted significant hetero-
geneity in technique for delineating a boost volume.
Techniques for delineation include single-parameter MRI,
multiparameter MRI (mpMRI), SPECT, and PET. Data
for SPECT are underwhelming, with 1 study noting no
correlation between tracer uptake and presence of cancer
on whole-mount pathology.22 MRI is regarded as the
current gold standard for imaging delineation. The
FLAME randomized trial used mpMRI for image delin-
eation.19 Test performance (as measured by sensitivity/
specificity or receiver operating characteristic analysis) is
worst for single-sequence MRI with performance
improving for multiparametric MRI, which is reflected in
current consensus guidelines recommending T2W (T2
Figure 2 Average EQD2Gy dose-volume histogram of the GTV, PROS-GTV, rectum, and bladder for all fractionations. Abbrevia-
tions: GTV Z gross tumor volume; PROS-GTV Z prostate excluding GTV.
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weighted) þ DWI (diffusion-weighted magnetic reso-
nance imaging) þ DCE (dynamic contrast enhanced
magnetic resonance imaging) for lesion detection.23
Chan et al24 examined the utility of choline PET
compared with MRI for lesion delineation. They found
that with shorter uptake times, choline PET resulted in a
lower accuracy (61.6%) compared with T2W MRI
(70.2%), but with a longer uptake time the accuracy of
PET surpassed MRI. They additionally noted that PET/
MRI together identified aggressive disease better than
either modality alone.24 In a recent study, Piert et al25
compared the accuracy of mpMRI and choline PET for
detecting clinically significant PCa. Ten patients under-
went mpMRI and PET/CT before radical prostatectomy.
Two radiologists independently determined tumor
boundaries based on mpMRI, and PET/CT data were
analyzed using a semiautomatic segmentation routine.
The results were compared with histopathologic regis-
trations, and all were found to grossly underestimate
tumor volume. However, when the information was
combined into a conglomerate volume, the percentage of
underestimated tumor volume improved significantly and
the necessary safety margin needed to safely cover the
entire tumor decreased from 11 to 15 mm to 9 mm.
There exists a reported correlation between PSMA
ligand expression/uptake and Gleason score, d’Amico risk
group, and features of tumor aggressiveness.26 This sug-
gests that PSMA PET may identify more clinically rele-
vant lesions compared with choline PET/CT or mpMRI.
Comparisons of PSMA PET/CT and mpMRI for DIL
delineation against postprostatectomy histopathology
have reported good sensitivity and specificity for both
modalities. Multiple studies have reported that the highest
degree of accuracy is achieved when combined PSMA
PET/MRI data are employed for lesion delineation.14-16
This supports the growing consensus that a hybrid of
mpMRI and PSMA PET data provides the most robust
imaging-guided delineation of DIL volumes.
Kuang et al27 used choline PET to derive boost vol-
umes and compared 2 dose fractionations. Whole prostate
PTV prescription was 79 Gy in both plans, with the
second plan incorporating simultaneous boost doses of
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Figure 3 Tumor control probability (TCP) for the GTV and PROS-GTV, NTCP for bladder and rectum, and probability of un-
complicated tumor control (Pþ) relative to rectal toxicity. Abbreviations: GTV Z gross tumor volume; PROS-GTV Z prostate
excluding GTV.
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100 Gy and 105 Gy to the IDL, defined by 60% and 70%
of maximum prostatic uptake on 18F-choline PET,
respectively. The boost plan was associated with signifi-
cantly higher TCP compared with the nonboost plan at all
4 a/b ratios examined (P < .001). They noted a small but
significant increase in NTCP for grade 2 late rectal
toxicity (2.2% vs 2.8%, P < .001). There was no sig-
nificant difference in bladder NTCP between the 2
plans.27 In a similar study from Zamboglou et al28 GTVs
were generated on the basis of an intraprostatic uptake of
68Ga-HBED-CC PSMA-PET. They used a threshold %
SUVmax of 30% to define GTV-PET. Two intensity
modulated radiation therapy plans were then generated for
each patient, the first consisting of 77 Gy to the whole
prostate and the second 77 Gy to the whole gland with
simultaneous integrated boost to GTV-PET up to 95 Gy.
Mean volume of generated GTV-PETs was 7.5  4.8 mL.
TCP-PET was found to be significantly higher for plan95
(100% vs 55%, P < .0001). No significant differences in
rectal or bladder NTCPs were observed between the 2
plans.28
Our study examined a variety of fractionation sched-
ules to simulate the effects on TCP and NTCP of a boost
to a DIL defined by PSMA PET uptake. With consider-
ation for delineating a biologically plausible volume, we
used a range of 23% to 40% SUVmax for definition of
GTV-PET (mean threshold SUVmax of 30%). Median
GTV-PET volume was 1.0 cm3 (0.4-1.8 cm3). Dose ob-
jectives and constraints were met for all plans except 2 of
the higher dose (50 Gy) 5-fraction boost protocol (F5BSH).
GTV-PET volume was not a limiting factor to boost
dose escalation. Instead, we encountered a more signifi-
cant effect with the location of the GTV-PET volume in
relation to surrounding OARs. Proximity of the DIL to the
rectum was the primary dose-limiting factor. For such
cases, to meet rectal constraints, we used a modified PTV
that is 5 mm away from the rectal wall. Despite these
modifications, GTV coverage of at least 99% of the pre-
scription boost dose was achieved for nearly all plans. In
patients 1 and 3, the proximity of the DIL to the rectum
precluded a F5BSH boost without exceeding rectal con-
straints. For all cases, the rectum and bladder doses were
generally lower in 5-fraction plans, mainly owing to
stricter planning constraints. We found a 7% to 10% in-
crease in TCP within the boost plans, which was statis-
tically significant compared with standard plans. NTCP
values were not statistically significantly different be-
tween standard and boost plans.
Our results compare favorably to the previously cited
studies, showing a significant increase in TCP with DIL
boost compared with standard plans with no significant
difference in NTCP. We recognize several limitations
with this work. Primarily, our study is limited by a small
sample size. The cases presented herein are representative
of typical DIL volumes and locations within the prostate
gland and offered sufficient data to discuss the proposed
dose escalation methodologies and compare different
fractionation schedules within the confines of this feasi-
bility study. In the future we hope to leverage increasing
access to PSMA PET to design larger-scale studies and
enable a more robust analysis. Our study also lacks
pathologic validation of our PSMA PET-derived vol-
umes. All patients underwent radical prostatectomy as
part of their definitive treatment, and work is ongoing to
complete coregistration of applicable histopathology to
PSMA PET data. Additionally, our model does not ac-
count for intrafraction sources of error.
There is mounting evidence to suggest that a boost to
an imaging-defined DIL would lead to improved out-
comes with minimal to negligible effects on toxicity rates.
To employ this technique clinically, more work is
required to standardize and validate a technique for DIL
definition. Several large clinical trials are actively inves-
tigating the use of DIL boost to improve outcomes. The
previously cited FLAME randomized trial, with a target
accrual of 571 participants, is powered to detect a 10%
improvement in 5-year freedom from BF. Initial reports
suggest that at a median follow-up of 55 months there are
no significant differences in toxicity rates between stan-
dard and boost arms. Forthcoming results from this and
similar trials will provide much-needed guidance on the
delineation of boost GTVs and the efficacy of DIL boost.
Although the FLAME protocol used mpMRI, the
described workflow and dose constraints could be readily
adapted for PSMA-PET based GTV delineation.
An additional boundary to clinical deployment is the
necessity for robust motion management to ensure proper
delivery of boost dose to the specified volume. Because of
the high dose gradients, risk of toxicity, and the required
geometric precision in DIL-boost treatments, assessment
of various sources of uncertainty and mitigation strategies
is warranted. First, the uncertainties in GTV contouring
may require adding large margins that would ultimately
lead to higher doses to the surrounding tissue. However,
we have recently demonstrated that mpMRI and PET may
enable more accurate GTV delineation, allowing smaller
margins and better dose sparing.13,29
Interfraction variations are now routinely and effec-
tively reduced by controlling rectum and bladder vol-
umes30 in conjunction with proper in-room image
guidance (usually daily cone beam CT for linear
acceleratorebased treatments). Furthermore, most DIL
boost and hypofractionation studies such as FLAME and
Hypo-FLAME require intraprostatic fiducial markers to
improve prostate localization.19
Intrafraction organ motion warrants special attention in
high-precision DIL-boost treatments compared with more
conventionally fractionated schedules. In a previous
experimental investigation, we showed that DIL boosts
can be safely achieved in the presence of intrafraction
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motion when using a PTV margin of 7 mm.31 More recent
studies have shown that tracking intraprostatic fiducial
markers and accounting for 6 degrees of freedom in
prostate motion can reliably monitor prostate position
during delivery with an accuracy of 0.2  1.3 and 0.1 
0.5 mm for rotation and translation, respectively.32
Fiducial tracking has been associated with lower
toxicity.30 Faster delivery (approximately 1 minute) using
flattening filter free mode has been shown to further
reduce the effects of intrafraction motion.33
In our institution, all patients undergo rectum and
bladder preparation, and fiducial markers are implanted
for all extreme hypofractionation cases. Cone beam CT
and 6 degrees of freedom couch are used for the initial
treatment setup, and triggered kV imaging is used for
prostate tracking as a quality assurance during treatment
within a 3 mm margin. All cases are planned with volume
modulated arc therapy and flattening filter free beams.
Based on the published evidence, we believe this process
offers safer and more reliable delivery of DIL-boost
treatments.
Conclusions
It is both feasible and safe to construct radiobiologi-
cally equivalent plans for a variety of dose fractionations
to deliver a boost to the DIL while meeting OAR con-
straints. The boost dose is limited by lesion size and
proximity to OARs, with less effect of fractionation
approach. Further study and better understanding of the
interplay among lesion morphology, anatomic factors,
and dosimetry are required.
Supplementary data
Supplementary material for this article can be found at
https://doi.org/10.1016/j.adro.2019.09.004
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